Loading
A phase 2 trial of Belzutifan, Cabozantinib in renal cell carcinoma, run by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), active and no longer recruiting.
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) is a phase 2 interventional study registered as NCT03634540 by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), with 118 participants planned, started 2018-09-27 and due to reach its primary completion in 2027-02-26. Interventions recorded: Belzutifan, Cabozantinib. Conditions listed: Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer. No results are recorded here; the registry entry is the source.
Shares Clear cell renal cell carcinoma, Cabozantinib, Anti-angiogenic therapy, Renal cell carcinoma.
Shares Belzutifan, Clear cell renal cell carcinoma, Anti-angiogenic therapy, Renal cell carcinoma.
Shares Belzutifan, Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Clear cell renal cell carcinoma, Anti-angiogenic therapy, Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Belzutifan, Cabozantinib, Anti-angiogenic therapy, Renal cell carcinoma.
Shares Belzutifan, Cabozantinib, Small-molecule kinase inhibitors.
Shares Belzutifan, Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.